Bicara Therapeutics (BCAX) CEO sells 15K shares and exercises options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar reported a mix of stock sales and option exercises in common stock. She sold a total of 15,000 shares in open-market transactions at weighted average prices of $20.3481 and $19.9619 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. She also exercised stock options to acquire 15,000 shares of common stock at an exercise price of $3.7898 per share. Following these transactions, she directly holds 377,152 shares of common stock and retains stock options covering 146,107 shares.
Positive
- None.
Negative
- None.
Insights
CEO executes routine exercise-and-sell under 10b5-1 plan.
Claire Mazumdar, CEO of Bicara Therapeutics, exercised stock options for 15,000 common shares at an exercise price of $3.7898 and sold 15,000 shares in open-market transactions around $20 per share. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025, indicating they were pre-scheduled rather than timed discretionarily.
After these transactions she continues to hold 377,152 common shares, along with stock options on 146,107 shares, so her remaining equity exposure is still sizable. The filing shows one derivative transaction and no remaining derivatives from this specific option lot, suggesting a standard compensation-driven exercise rather than a strategic reduction of her overall position.
Insider Trade Summary 10b5-1
Net Seller: 15,000 shares ($300,579)
Net Sell
4 txns
Insider
Mazumdar Claire
Role
Chief Executive Officer
Sold
15,000 shs ($301K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 15,000 | $3.7898 | $57K |
| Sale | Common Stock | 12,022 | $19.9619 | $240K |
| Sale | Common Stock | 2,978 | $20.3481 | $61K |
Holdings After Transaction:
Stock Option (Right to Buy) — 146,107 shares (Direct, null);
Common Stock — 377,152 shares (Direct, null)
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.52 to $20.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.25 to $20.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Open-market sale 1: 2,978 shares at $20.3481
Open-market sale 2: 12,022 shares at $19.9619
Options exercised: 15,000 shares at $3.7898
+3 more
6 metrics
Open-market sale 1
2,978 shares at $20.3481
Weighted average sale price for one trade lot of common stock
Open-market sale 2
12,022 shares at $19.9619
Weighted average sale price for second trade lot of common stock
Options exercised
15,000 shares at $3.7898
Exercise of stock options into common stock
Shares owned after transactions
377,152 shares
Direct common stock holdings following reported trades
Options remaining
146,107 shares
Stock options outstanding after the reported exercise
10b5-1 plan adoption date
February 12, 2025
Date CEO adopted pre-arranged trading plan for these sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did Bicara Therapeutics (BCAX) CEO report?
The CEO reported selling 15,000 shares of common stock in open-market trades and exercising options for 15,000 shares at $3.7898 per share. These combined moves reflect an exercise-and-sell pattern common in equity compensation programs.
Were the Bicara Therapeutics (BCAX) CEO’s stock sales pre-planned?
Yes. A footnote states the transactions were executed under a Rule 10b5-1 trading plan adopted on February 12, 2025. Such plans pre-schedule trades, reducing the likelihood that sale timing reflects short-term views on the stock.
What stock options did the Bicara Therapeutics (BCAX) CEO exercise?
She exercised stock options covering 15,000 shares of common stock at an exercise price of $3.7898 per share. These options were part of a grant vesting in sixteen equal quarterly installments beginning August 8, 2023, subject to continued service.
How many stock options does the Bicara Therapeutics (BCAX) CEO still hold?
After the reported option exercise, the CEO holds stock options on 146,107 shares of common stock. This remaining derivative position, alongside 377,152 owned shares, shows continued exposure to Bicara Therapeutics’ equity.